Sionna therapeutics announces positive phase 1 data for nbd1 stabilizers sion-719 and sion-451 and advances both programs in clinical development for cystic fibrosis

Sion-719 and sion-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a sionna dual combination sionna plans to advance sion-719 to a phase 2a proof-of-concept add-on to standard of care trial in cystic fibrosis patients, and sion-451 to a phase 1 healthy volunteer dual combination trial next trials to initiate in the second half of 2025 with topline data expected in mid-2026 sionna to hold a conference call today at 8:00 a.m. et waltham, mass.
SION Ratings Summary
SION Quant Ranking